Three Platforms Used to Monitor Cytokines and the Complement System
Monitoring both cytokines and complement factors in drug development has become increasingly important, as the movement toward personalized treatments for cancers and genetic diseases has spurred research and development into biologics, vaccines, and small molecules that can have unintended consequences due to their immunomodulatory effects.
Must-Read Scientific Posters Presented by Our Preclinical Experts
LATEST SCIENTIFIC POSTERS PRESENTED BY OUR PRECLINICAL EXPERTS
Hot off the press! We're excited to showcase our latest collection of 11 new scientific posters, unveiled at the
63rd Annual Society of Toxicology (SOT) Meeting.
Dive deep into a series of preclinical findings:
• Sinclair Nanopig™: From Multi-Omics Characterization to Pharmacology and Toxicology Validation: Underline Drug Metabolism and Immune System Presented by Yafei Chen, Senior Research Fellow, Pathology Services
• Cross-Comparison of Immunophenotyping Assay Performance in Naïve Filipino, Mauritian, and Cambodian Nonhuman Primates Presented by Derek Hanson, Principal Scientist
• Historical Background Data in Juvenile Cynomolgus Monkeys: Comparative Immunotoxicology and Pathology of Different Origins Presented by Narine Lalayeva, Associate Director, Safety Assessment
• Cross-Comparison of Biomarker Assay Performance in Naïve Philippines, Cambodian, and Mauritius, and Non-Naïve Mauritius Cynomolgus Macaque Nonhuman Primates Presented by Catherine Schilffarth, Associate Director, Operations, Laboratory Sciences
• 28-Day Intranasal Toxicity Study of MMS019 in Sprague Dawley Rats and Dogs Presented by Kyle Klepner, Senior Scientist, Study Director, Safety Assessment
• Tissue Biopsy Collections in Nonhuman Primates During Toxicology Studies: A Comparison of Findings with Animals Not Sampled Presented by Narine Lalayeva, Associate Director, Safety Assessment
• Incidence of Neutralizing Adeno-Associated Viral Antibody Subtypes in Cynomolgus Monkeys of Cambodian, Mauritius, and Philippines Origins Presented by Julie Forget, Senior Director, Safety Assessment
• Development of a Novel Early Intervention Stabilization for Abdominal Aortic Aneurysms Presented by Timothy J. Madsen, Associate Scientific Director, General Toxicology
• Development of a Canine Prostatectomy Model for Use in the Toxicity Evaluation of Oncology Drugs Presented by Ahmed Abdalla, Associate Scientist, Study Director
• Comparison of Safety Pharmacology End Points Used on Toxicology Studies Across Differing Cynomolgus Monkey Origins Presented by Jean-Christophe Queudot, Associate Director, Safety Pharmacology
• Clinical Pathology Reference Data for the Philippine Cynomolgus Monkey for Preclinical Toxicology Studies Presented by Dr. Johanna Rigas, Veterinary Clinical Pathologist
Questions? Speak with one of our experts about your small or large molecule preclinical projects. We can get your study started within the next two months!
Top 5 Scientific Resources in CNS Clinical Trials
CNS Center of Excellence Resource Library
Altasciences has an extensive understanding of psychiatric and neurologic disorders, stemming from our decades of conducting complex studies in various therapeutic indications impacting the central nervous system.
Here are some of our most insightful scientific resources in the area of CNS drug development:
Webinar: A Square Peg in a Round Hole–Navigating the Unique Attributes of Psychedelic Drug Development
Altasciences’ panel of experts discuss the FDA’s recently published guidelines for early-phase clinical development of psychedelics and the assessment of abuse potential. Watch Now
The Altascientist: Central Nervous System
Early-phase development of CNS-acting drugs is a complex, challenging undertaking.
In this article, we provide a detailed overview of the multiple facets you need to consider during the planning and conduct of your CNS-active drug development. Learn More
The Altascientist: CNS, Psychedelics, and Other Schedule I Drugs
In this scientific journal, we uncover the regulatory environment and challenges, the required preclinical and clinical studies specific to Schedule I or Class I (CI) drugs, and the manufacturing considerations for CNS-active drugs. Learn More
The Altascientist: Studying the Effects of Drugs on Driving
Driving simulation studies are required by the FDA when preclinical and early clinical studies show that a drug may cause somnolence or impair cognition. Discover the challenges of driving simulation clinical testing. Learn More
The Altascientist: Human Abuse Potential Studies
The 2017 FDA guidance states that a broad range of CNS drugs require human abuse potential (HAP) studies to evaluate the abuse liability of drugs in development before a drug reaches the market. The complicated regulatory pathway for HAP requires individualized consulting for each type of study. Watch Now
Speak with an expert today to learn more about our CNS solution.
Have five more minutes? Check out these webpages:
• CNS Clinical Trials
• Human Abuse Potential<
• Driving Simulation<
We Want to Say Thanks!
Thank You for Being You
Here’s to you… who forge new paths into the unknown and shape the future of medicine for generations to come.
To show our appreciation for the rich tapestry of perspectives and experiences that you bring to drug development, we made you this video:
Thank you for entrusting Altasciences as your partner in helping you create novel ways to fight disease.
First-in-Human Solution for Small and Large Molecules
Clinical Pathology Reference Data for the Philippine Cynomolgus Monkey for Preclinical Toxicology Studies
Comparison of Safety Pharmacology End Points Used on Toxicology Studies Across Differing Cynomolgus Monkey Origins
Cross-Comparison of Biomarker Assay Performance in Nonhuman Primates